These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 15772461)
1. Comparison of the impact of pro- and antiinflammatory immune processes at the two immune-deviated sites, eye and solid tumor and possible consequences for the antitumoral therapy with fever inducers. Schramm H Forsch Komplementarmed Klass Naturheilkd; 2005 Feb; 12(1):37-46. PubMed ID: 15772461 [TBL] [Abstract][Full Text] [Related]
2. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks. Dohmen W; Breier M; Mengs U Anticancer Res; 2004; 24(2C):1231-7. PubMed ID: 15154652 [TBL] [Abstract][Full Text] [Related]
3. Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract. Klein R; Classen K; Fischer S; Errenst M; Scheffler A; Stein GM; Scheer R; von Laue HB Eur J Med Res; 2002 Aug; 7(8):359-67. PubMed ID: 12204844 [TBL] [Abstract][Full Text] [Related]
4. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines. Chen PW; Ksander BR Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019 [TBL] [Abstract][Full Text] [Related]
5. See no evil, hear no evil, do no evil: the lessons of immune privilege. Niederkorn JY Nat Immunol; 2006 Apr; 7(4):354-9. PubMed ID: 16550198 [TBL] [Abstract][Full Text] [Related]
6. Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro. Kelter G; Schierholz JM; Fischer IU; Fiebig HH Anticancer Res; 2007; 27(1A):223-33. PubMed ID: 17352237 [TBL] [Abstract][Full Text] [Related]
7. [Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks]. Gabius S; Gabius HJ Dtsch Med Wochenschr; 2002 Mar; 127(9):457-9. PubMed ID: 11870561 [No Abstract] [Full Text] [Related]
8. [Immune reactions in the eye]. Esterre P; Auzemery A; Godinaud P Arch Inst Pasteur Madagascar; 1996; 63(1-2):19-23. PubMed ID: 12463010 [TBL] [Abstract][Full Text] [Related]
9. Immunologic effects of mistletoe lectins: a placebo-controlled study in healthy subjects. Huber R; Rostock M; Goedl R; Lüdtke R; Urech K; Klein R J Soc Integr Oncol; 2006; 4(1):3-7. PubMed ID: 16737665 [TBL] [Abstract][Full Text] [Related]
10. Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Mrass P; Weninger W Immunol Rev; 2006 Oct; 213():195-212. PubMed ID: 16972905 [TBL] [Abstract][Full Text] [Related]
11. Immune deviation in relation to ocular immune privilege. Streilein JW; Ksander BR; Taylor AW J Immunol; 1997 Apr; 158(8):3557-60. PubMed ID: 9103414 [TBL] [Abstract][Full Text] [Related]
13. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Karin M; Lawrence T; Nizet V Cell; 2006 Feb; 124(4):823-35. PubMed ID: 16497591 [TBL] [Abstract][Full Text] [Related]
14. Myeloid-derived suppressor cell role in tumor-related inflammation. Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992 [TBL] [Abstract][Full Text] [Related]